Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)

Clinical trial NCT04622007 · UNKNOWN

Trial details

NCT number: NCT04622007
Sponsor: Effector Therapeutics
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2021-06-02
Primary completion: 2024-10-14
Enrollment: 68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.